VOA慢速英语(翻译+字幕+讲解):冠状病毒患者参与抗病毒药物研究
日期:2020-04-16 18:24

(单词翻译:单击)

[W]hc_,WtewX)I

听力文本

)SkH9]UNfQy*

Coronavirus Patients Rush to Join Studies of Gilead Drug
The new coronavirus COVID-19 made Dr. Jag Singh a patient at his own hospital.
A lung infection made it difficult for him to breathe. His doctors at Massachusetts General said he needed to make a decision about life support while in intensive care.
Then, they offered him a chance to test remdesivir. The experimental drug has had some good results when used against other coronaviruses. Singh, a heart specialist, said ‘yes' immediately.
COVID-19 patients around the world have been joining remdesivir studies in the past few weeks.
The interest has been so great that the U.S. National Institutes of Health (NIH) is expanding its study. It has nearly reached its first goal of 440 patients. The California company Gilead Sciences makes the drug. It is increasing its own studies too.
"I would enroll my family" immediately, said Dr. Libby Hohmann. She placed Singh and nearly 30 other patients in the NIH study at Massachusetts General.
For most people, COVID-19 causes moderate symptoms. Some patients, however, get a lung infection which requires hospitalization. The risk of death is greater for older people and those with other health problems.
The drug remdesivir has been used in animal testing against two similar coronaviruses, SARS and MERS. The drug helped prevent infection and reduced the symptoms if it was taken early. The testing is farther along than other possible drugs and may lead to government approval for treatment.
The drug-maker Gilead has given remdesivir to more than 1,700 patients. Its chief executive Dan O'Day wrote that many people have asked for the drug but the company is "taking the ethical, responsible approach." He said more people will be helped if studies prove the drug to be safe and effective.
O'Day said his company has drug treatment for more than 140,000 patients. It is providing the drug for free for now. It has set a goal of making treatments for 500,000 patients by October and more than a million by the end of the year.
Gilead also gave remdesivir to China for two studies expected to have results by the end of the month. Other studies have begun in Asia and Europe.
"There's so much anxiety about the disease that the patients are quite interested" and no one offered the chance has refused, said Dr. Arun Sanyal. He is the study leader at Virginia Commonwealth University in Richmond.
The NIH study, however, is the most rigorous of all the tests. It compares remdesivir to placebos, and neither patients nor doctors know who is getting what until the end of the study.
I'm Anna Matteo.

重点解析

1.intensive 加强的

fxO&vW5J+62]O!YnX1cv

There we received several weeks of intensive training.
在那里我们受了几星期的集中训练1a%L&eCfp%)

2.rigorous 严格的

TEcu8r2Gf.VM

He is a very rigorous man, very persnickety.
他是个很严厉的人,非常挑剔wp%;NNIJw1

3.anxiety 焦虑

I,qMHjSIbnp)K4[W

He has exhibited symptoms of anxiety and overwhelming worry
他表现出焦躁不安和过度忧虑的症状zx+]S,!^._PKZ%3-a*%

4.treatments 治疗

bw+o!2P@H%@jxw

His research was used in planning treatments for hyperactive children.
他的研究被用来为多动的儿童设计治疗方案ja3gXPYm3Z0C

5.His doctors at Massachusetts General said he needed to make a decision about life support while in intensive care.

make a decision 做决定

vXu_|3B9q!;[%(Nj1.

Think over the matter and then make a decision.
这件事情斟酌斟酌再定4t%3bQ25mM#
Let me pause on these matters for a time before I make a decision.
让我把这些事情好好想一想再作决定PXgCHxVSz]

6.A lung infection made it difficult for him to breathe.

made it difficult to 使某事变困难

o~e-JWYr=cY

The economy of the times made it difficult to support centralized rule.
当时的经济状况不利于实行集权统治6PS9v@LH^=s*7.
The box's bulk made it difficult to carry.
箱子体积太大,很难搬运blB-s7SIIg|j(wbjC!_

参考译文

IB9Axb_FBTDrEs-Xs-

冠状病毒患者参与抗病毒药物研究
新冠状病毒引发的新冠肺炎让贾格·辛格医生成为自家医院的患者cUcUF84te3ipnTkP
肺部感染导致他呼吸困难_eo9bI|HUg1B9LN@Yo。来自马萨诸塞州总院的医生告诉他,在重症监护期间,他需要对自己的生命支持一事做出决定^rS1t[qRKKnqC
然后,医院为他提供了一个测试瑞德西韦药物的机会PLNeIb(Ybp*X+QB。该实验药物在治疗其他一些冠状病毒时发挥了良好的疗效-nJNn+DOL5e(。心脏病专家辛格当即答应进行测试Rq1i-f!65Fhtt-
过去几周,世界各地的新冠肺炎患者纷纷参加了瑞德西韦药物的研究.vF-T6H|,2KK6

RV6Lk!qMXCqA1!JBfUt

冠状病毒患者参与抗病毒药物研究.jpg
由于人们对该药物的研究兴趣浓厚,美国国立卫生研究院(NIH)为此扩大了其研究范围yAwZBPUQw~U_;5m]sm。目前即将实现其首个目标——测试440位患者(g|+Y+_~EC^j]。该药物由加利福尼亚的吉利德科学公司研制,该公司也增加了对此药物的内部研究QRXmruS86L6a*
利比·霍曼(Libby Hohmann)博士表示:“我会立刻让家人参加”D0lrqhk6bd^QPR[H-GfS。她将麻省总院的辛格和其他近30名患者纳入了美国国立卫生研究院的研究中H3CP94Uj]RW2_4saox
对于大多数人来说,新冠肺炎会引发中度症状Bj_8]@P^p%D9。然而,某些患者会出现肺部感染且需要住院治疗GK|OOR(GoKHhN。对于老年人和其他有健康问题的人来说,(感染后)死亡的风险较高s_nOtHGByp7kO]XXiko
在对抗两种相似冠状病毒“非典”(SARS)和“中东呼吸综合征”(MERS)时,瑞德西韦药物已经被用于动物试验(_&Wybn|s]^U。如果及早服用,有助于预防感染并减轻病症0pdQ&P6bVp~N4E^n@1。与其他测试药物相比,该药物测试进展更快且有可能获得政府批准用于治疗U&)0;c6q4]2
该药物的生产商吉利德公司已经为1700多名患者提供了瑞德西韦药物1q1RdQXos36=7J~tr!G。该公司首席执行官丹·奥戴(Dan O’Day)写道,许多人想要获得药物,但公司仍需要遵循“合规且负责的方式”OvbMHh_L9-。他说,如果研究证明了该药物安全有效,那么更多的人将得到帮助0kA~y7DXyG@tNs
奥戴表示,该公司为14万多患者提供药物治疗,且目前该药物是免费的|U]CWF((8w7。该公司的目标是到10月底为50万患者提供治疗,并在年底前为100万多万人提供治疗;e-xnf*5N+
吉利德公司还向中国提供了瑞德西韦药物用于两项研究,预计将在本月底得出结果qr60VSB^PcW9)h|。亚洲和欧洲其他地区也纷纷开展了研究工作ps%qq,lXmBKq5E)v&-
阿伦·桑亚尔博士说:“该疾病引发了太多的恐慌,以至于患者都(对测试)很感兴趣”,没有人会拒绝这次测试研究的机会HM;si05q,mmXMOH。桑亚尔博士是里士满弗吉尼亚联邦大学的研究负责人=FeS@Pj0UY,6K+L9FIAY
但是,美国国立卫生研究院的研究是所有测试中最严格的F5R@quv=]o[xCJf8#。它将瑞德西韦与安慰剂进行比较,在研究结束前,无论是患者还是医生都无法知晓所服用的药物@In(9gzhW,RAQ
安娜·马特奥为您播报En|^Sr~KPR;

译文为可可英语翻译,未经授权请勿转载!

hdg2C,JZ&S|b4fDHHyl[scH5h9o,63oMAKC#W.*+9c_H4P
分享到